A Leap Forward in MS Research For years, scientists have puzzled over what causes multiple sclerosis (MS), a neurological ...

A Norwegian-Swedish clinical trial published in the New England Journal of Medicine demonstrates that rituximab, a low-cost B ...

An experimental MS therapy given as a nasal spray has started dosing its final participant in a Phase 2a trial of people with ...

Add Yahoo as a preferred source to see more of our stories on Google. When you buy through links on our articles, Future and its syndication partners may earn a commission. Dr. Alberto Ascherio (left) ...

NASHVILLE, Tennessee — For the first time, the majority of patients with multiple sclerosis (MS) in the United States are, or soon will be, over age 55, a phenomenon that's driving a shift in ...

MS researcher Professor Hanneke Hulst shares how growing up with a mother who had MS inspired her career in brain research in ...

Multiple sclerosis research focuses on the early years of life by Friederike Fellenberg, NAKO e.V. / NAKO Gesundheitsstudie edited by Sadie Harley, reviewed by Robert Egan Editors' notes The GIST ...

Speakers at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2024 focused their attention on avenues to improve research accessibility for investigators and care access ...

In MS, immune system cells mistakenly attack myelin. With stem cell treatment, doctors use chemotherapy to destroy these existing immune cells. Then, they introduce the new stem cells, which are not ...

A Norwegian Swedish clinical trial published in the New England Journal of Medicine (NEJM) demonstrates that rituximab, a low ...